The application of Gd-EOB-DTPA enhanced MRI and MDCT in the diagnosis of hepatitis B cirrhosis combined with small liver cancer

Abstract

Abstract: Objective To exploring the diagnostic value of specific contrast agent gadolinium oxalate disodium (Gd EOB DTPA) enhanced magnetic resonance imaging (MRI) and multi phase enhanced multi row spiral CT (MDCT) in the diagnosis of hepatitis B cirrhosis with small hepatocellular carcinoma (sHCC). Methods 80 patients with hepatitis B cirrhosis and sHCC who received treatment in The 904th Hospital of the Joint Logistics Support Force of PLA from December 2020 to December 2023 were selected as the study subjects. All patients underwent Gd-EOB-DTPA-MRI and MDCT scans after admission, with a scanning interval of less than 4 weeks, and the diagnostic value of the two techniques for sHCC was analyzed. Results A total of 99 lesions were detected in 80 sHCC patients. The number of lesions detected by Gd-EOB-DTPA-MRI was 99 (100%). The nodule volume was (3.52±0.79) cm³. The typical lesion detection rate was 97.98 (97/99). The number of lesions detected by MDCT was 87 (87.88%), the nodule volume was 2.86±0.71) cm³, and the typical lesion detection rate was 78.16 (68/87). The difference between the two groups was statistically significant (χ²=12.774, t=2.863, χ²=18.061; P<0.05). During the hepatobiliary phase of Gd-EOB-DTPA-MRI, there was 1 lesion with high enhancement (1.01%), 5 lesions with equal enhancement (5.05%), and 92 lesions with low enhancement (92.93%). During the arterial phase of MDCT, there were 80 lesions with high enhancement (91.95%), 7 lesions with equal enhancement (8.05%), and 0 lesions with low enhancement (0.00%). Gd EOB DTPA MRI examination revealed 17 lesions (17.17%) with no significant enhancement at the edge of the capsule, which was lower than MDCT (31 lesions, 35.63%) (χ²=8.242, P<0.05). Conclusion Compared with MDCT, Gd EOB DTPA-MRI improves the detection rate of sHCC in patients with hepatitis B and cirrhosis, which has good diagnostic value.

Key words: Disodium gadolinium sulfate, Magnetic resonance imaging, Multi phase enhanced multi row spiral CT, Hepatitis B, Liver cirrhosis, Small hepatocellular carcinoma

GE Qi, YIN Hui-kang, BAI Ling, YE Dai-xi. The application of Gd-EOB-DTPA enhanced MRI and MDCT in the diagnosis of hepatitis B cirrhosis combined with small liver cancer[J]. Chinese Hepatolgy, 2025, 30(8): 1104-1107.

References

[1] Ghanaati H, Mohammadifard M, Mohammadifard M. A review of applying transarterial chemoembolization (TACE) method for management of hepatocellular carcinoma[J]. J Family Med Prim Care,2021,10(10):3553-3560.
[2] 张鹭,江建宁.原发性肝癌发病机制和治疗的最新进展[J].肝脏,2020,25(5):455-458.
[3] 陈小萍,胡维杰,王婷婷.肝硬化背景下小肝癌微血管侵犯及复发的CT表现[J].肝脏,2022,27(10):1076-1079.
[4] Gu K, Jeon T Y, Yoo S Y, et al. Gd-EOB-DTPA MRI for focal nodular hyperplasia-like lesions in pediatric cancer survivors[J]. Eur Radiol,2021,31(1):283-291.
[5] 王宝锋,马彦高,李义,等.增强MRI扫描在乙型肝炎肝硬化背景下对原发性肝癌的诊断价值分析[J].实用肝脏病杂志,2022,25(4):554-557.
[6] 张瑜,陈琨.血小板4项参数联合血清AFP水平检测对乙型肝炎肝硬化肝癌的诊断价值研究[J].国际检验医学杂志,2020,41(23):2921-2924.
[7] 张瑶,张林启,陈景标,等.钆贝葡胺与钆塞酸二钠增强MRI诊断HBV相关肝癌包膜的效能比较[J].中华肝脏外科手术学电子杂志,2020,9(1):72-76.
[8] 刘茂童,张涛,张学琴,等.Gd-EOB-DTPA增强MRI对CK19阳性小肝癌(≤3 cm)的评估价值[J].放射学实践,2023,38(9):1101-1107.
[9] 吕婷婷,秦丽莉,那民,等.定量分析Gd-EOB-DTPA增强MRI对预测肝细胞肝癌的临床应用价值[J].中国CT和MRI杂志,2021,19(5):63-66.
[10] Qing Z, Yuan H, Hao X, et al. Diagnostic value of CT delayed phase images added to Gd-EOB-DTPA MRI for HCC diagnosis in LR-3/4 lesions[J]. Int J Gen Med,2023,16:2383-2391.
[11] Wang L, Liang M, Feng B, et al. Microvascular invasion-negative hepatocellular carcinoma: prognostic value of qualitative and quantitative Gd-EOB-DTPA MRI analysis[J]. Eur J Radiol,2023,168:111146.
[12] Tanaka T, Nishida H, Mie K, et al. Assessment of hepatitis and fibrosis using Gd-EOB-DTPA MRI in dogs[J]. Vet Rec Open,2020,7(1):e000371.
[13] 贾乃龙,王松海,李传资.肝脏≤2 cm局灶性病变动态增强MRI和MDCT的诊断价值[J].中国CT和MRI杂志,2020,18(3):4-6.
[14] 张岚,黎雅琳,韩鼎盛,等.微小肝细胞癌(≤1 cm)的Gd-EOB-DTPA增强MRI表现[J].中国医学计算机成像杂志,2023,29(1):39-43.
[15] Cheng J, Li X, Wang L, et al. Evaluation and prognostication of Gd-EOB-DTPA MRI and CT in patients with macrotrabecular-massive hepatocellular carcinoma[J]. J Magn Reson Imaging, 2023,15:29052.
[16] 王德志,胡海洋,郭长华,等.钆贝葡胺核磁共振增强与CT多期增强扫描对肝硬化伴小肝癌诊断的对比研究[J].中西医结合肝病杂志,2021,31(5):449-451.
[17] 朱心雨,郭立,张雨柔,等.基于钆塞酸二钠增强的MRI在肝功能评估中的应用进展[J].山东医药,2023,63(34):108-111.
[18] Li X Q, Wang X, Zhao D W, et al. Application of Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) in hepatocellular carcinoma[J]. World J Surg Oncol,2020, 18(1):219.
[19] 刘敏,张进,陆玉.Gd-EOB-DTPA动态增强MRI与64排增强CT评估乙型肝炎肝硬化背景小肝癌病灶的差异[J].肝脏,2020(12):1278-1281.
[20] 李锦红,闫苗苗,张炜.增强MRI肝癌成像中转运蛋白OATP1B3表达及其临床亚类分析[J].中西医结合肝病杂志,2022,32(3):238-242,247.
[21] Hope T A, Fowler K J, Sirlin C B, et al. Hepatobiliary agents and their role in LI-RADS[J]. Abdom Imaging,2015,40(3):613-625.